Search

Search Constraints

You searched for: Author/Creator Dimopoulos, Meletios

Search Results

1. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Issue 1 (2nd January 2017)

2. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Issue 12 (December 2018)

3. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. Issue 1 (2nd January 2020)

4. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Issue 10245 (18th July 2020)

5. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Issue 1 (January 2022)

6. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Issue 12 (December 2018)

7. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Issue 2 (28th January 2021)

8. European Perspective on Multiple Myeloma Treatment Strategies in 2014. (25th July 2014)

9. European Perspective on Multiple Myeloma Treatment Strategies in 2014. (25th July 2014)

10. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Issue 8 (2nd July 2020)